Viatris (VTRS) Other Non Operating Income (2019 - 2026)
Viatris' (VTRS) quarterly Other Non Operating Income came in at -$47.5 million in Q1 2026, up 52.17% year-on-year from -$31.2 million in Q1 2025, and down 54.72% quarter-over-quarter from -$30.7 million in Q4 2025.
Viatris (VTRS) Other Non Operating Income (2019 - 2026) Analysis & Trends
Viatris' Other Non Operating Income history runs 8 years deep, the most recent figure standing at -$47.5 million for Q1 2026.
- On a quarterly basis, Other Non Operating Income rose 52.17% year-over-year to -$47.5 million in Q1 2026; TTM through Mar 2026 was -$478.8 million, a 421.57% decrease from a year earlier, with the FY2025 full-year figure at -$530.6 million, down 536.97% from the prior year.
- Other Non Operating Income slipped to -$47.5 million in Q1 2026 per VTRS's latest filing, from -$30.7 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.8 billion in Q4 2022 and bottomed at -$333.5 million in Q2 2025.
- The 5-year median for Other Non Operating Income is -$6.1 million (2024), against an average of $80.5 million.
- Across the five-year window, Other Non Operating Income surged 8198.17% in 2022 and sank 5367.21% in 2025, its largest moves.
- Year by year, Other Non Operating Income stood at $1.8 billion in 2022, then sank by 114.28% to -$259.6 million in 2023, then surged by 101.31% to $3.4 million in 2024, then tumbled by 1002.94% to -$30.7 million in 2025, then plunged by 54.72% to -$47.5 million in 2026.
- Per Business Quant, the three latest VTRS Other Non Operating Income figures stand at -$47.5 million (Q1 2026), -$30.7 million (Q4 2025), and -$67.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.50 Mn |
| Dec 31, 2025 | -30.70 Mn |
| Sep 30, 2025 | -67.10 Mn |
| Jun 30, 2025 | -333.50 Mn |
| Mar 31, 2025 | -99.30 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Sep 30, 2024 | 10.20 Mn |
| Jun 30, 2024 | -6.10 Mn |
| Mar 31, 2024 | 139.10 Mn |
| Dec 31, 2023 | -259.60 Mn |
| Sep 30, 2023 | 92.00 Mn |
| Jun 30, 2023 | 107.50 Mn |
| Mar 31, 2023 | 69.90 Mn |
| Dec 31, 2022 | 1.82 Bn |
| Sep 30, 2022 | 20.60 Mn |
| Jun 30, 2022 | -13.50 Mn |
| Mar 31, 2022 | -33.70 Mn |
| Dec 31, 2021 | 21.90 Mn |
| Sep 30, 2021 | -5.80 Mn |
| Jun 30, 2021 | -4.20 Mn |